Drugs / Dimedrol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07472270 Background | Mar → Dec 2026 expected | cirrhosis of liver | Vinmec Research Institute of Stem Cell and Gene Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimedrol | “Dimedrol 20 mg will be administered intravenously 15-30 minutes prior to EV infusion.” NCT07472270 ↗ |
| Route | Intravenous | “Dimedrol 20 mg will be administered intravenously 15-30 minutes prior to EV infusion.” NCT07472270 ↗ |